Purpose: I-labeled human serum amyloid P component (SAP) is used clinically only in the UK for imaging visceral amyloidosis to assist with diagnosis, disease staging, and monitoring response to therapy. We compare a new amyloid-reactive probe, peptide p5, with SAP for imaging amyloidosis. Procedures: Dual-energy SPECT/CT images were acquired of 125 I-labeled SAP and 99m Tclabeled p5 in mice with systemic AA amyloidosis (n=3). Twelve organs and tissues were harvested for radiotracer biodistribution assessment and for micro-autoradiographic analysis.
Introduction
A myloidosis is a complex pathology associated with the deposition of protein fibrils, heparan sulfate proteoglycans, and serum amyloid P component (SAP) in various organs and tissues causing dysfunction and death. Amyloid, composed of different protein fibrils, deposits in visceral organs leading to a number of disorders including light chain (AL), reactive (AA), or senile systemic (ATTR) amyloidosis [1, 2] . Radioiodinated serum amyloid P component is the only routinely used radiotracer to detect the whole body burden of visceral amyloid in patients [3] [4] [5] ; however, due to its human origin, it is not approved for use in the USA. As an alternative, we have identified a 31-mer heparin-binding peptide that accumulates rapidly and specifically in visceral AA amyloid deposits in a preclinical murine model of the disease. The peptide, designated p5, bound amyloid within 1 h p.i. and remained associated with the deposits for up to 24 h, as evidenced in single photon emission computed tomographic (SPECT) images, by measurements of radioactivity biodistribution, and in micro-autoradiographs [6] .
The p5 peptide is a chemically synthesized 31-amino acid reagent [7] which allows for rapid imaging and may have advantages for approval for clinical trials in the USA. Such a small peptide is able to penetrate vascular endothelium and be rapidly cleared from the circulation if not bound to target, and is likely to be non-immunogenic [8] [9] [10] .
The aim of this study was to validate the efficacy of radiolabeled p5 peptide as an alternative tracer for imaging visceral amyloid in vivo. Amyloid deposits, even in experimental animals, can vary between individuals. For this reason, we chose to compare the p5 peptide and SAP by using dual-energy SPECT imaging and biodistribution measurements in the same animals (see Table 1 for physical comparison). Both tracers were selectively retained by amyloid in the visceral organs of mice with AA amyloidosis; however, 99m Tc-p5 peptide accumulated significantly better in pancreatic and intestinal amyloid relative to SAP. These data indicate that imaging with p5 affords a viable alternative to SAP for detecting deposits in patients with visceral amyloidosis.
Materials and Methods

Animals
AA amyloidosis was studied in H2-L d -huIL-6 Tg Balb/c (C) transgenic mice that constitutively express the human interleukin-6 transgene resulting in an acute "inflammatory" state with 1-4 mg/ml circulating serum amyloid protein A, the AA amyloid precursor protein [11, 12] . Amyloid was induced in 8-week-old female mice by i.v. administration of 100 μg of isolated AA amyloid fibrils (AEF) in 100 μl of sterile phosphate-buffered saline (PBS). Mice used in these experiments were 6 weeks post-induction. All animal procedures were performed under the auspices of protocols approved by the University of Tennessee Animal Care and Use Committee. The University of Tennessee is an AAALAC-Iaccredited institution.
Radiotracer Preparation
Human SAP was isolated from autopsy-derived amyloidcontaining spleen by first washing homogenized tissue in Tris-buffered saline containing 2 mM CaCl 2 . SAP was eluted from washed residue by addition of buffered saline containing 10 mM EDTA and was further purified by affinity chromatography using O-phosphoryl ethanol Sepharose. Purified SAP was radioiodinated with 125 I (PerkinElmer, Waltham, MA), using chloramine T, and purified by gel filtration chromatography, as previously described [13] . Peptide p5 was synthesized (Keck Laboratories, New Haven, CT) and then purified by reverse-phase HPLC before being labeled with 99m Tc [14] or 125 I [6] . 99m Tclabeled p5 peptide for imaging and biodistribution studies was diluted into 0.1% sterile gelatin in PBS and purified by gel filtration on a 5-ml PD10 column equilibrated in gelatin/PBS. Radioiodinated p5 was similarly prepared for micro-autoradiographic studies. Peak fractions of radiotracer were pooled, and the product's radiochemical purity was established by SDS polyacrylamide gel electrophoresis analyzed by phosphor imaging (Cyclone Storage Phosphor System, PerkinElmer, Shelton, CT).
SPECT/CT Imaging
Each of three AA mice was injected with 6.5 μg of 125 I-SAP (5.1±0.3 MBq) and 22 h thereafter 7.5 μg of 99m Tc-p5 (36.6± 3.5 MBq-both injected doses were estimated based on measuring the remaining activity in the syringe after each injection) in the lateral tail vein. After a further 2 h, the mice were given ∼500 μl of a 1:1 dilution of Iohexol in PBS i.p. 1 min before being euthanized by an isoflurane inhalation overdose and image data collected. Dual-energy SPECT images were acquired sequentially using an Inveon trimodality imaging platform (Siemens Preclinical Solution, Knoxville, TN; [15] ). Low ( 125 I; 25-45 keV: calculated acquisition sensitivity=244 cps/MBq) then high ( 99m Tc; 126-154 keV: calculated acquisition sensitivity=286 cps/MBq)-energy gamma photons were acquired using a helical SPECT acquisition protocol with sixty 16-s projections and 90 mm of bed travel. A 0.5-mm-diameter five-pinhole (Mouse Whole Body) collimator was used at 30 mm from the center of the field of view. Data were reconstructed using a 3D maximization a posteriori algorithm (zoom=1, β=1, 16 iterations, 3 subsets) with 0.5-mm isotropic voxels and with x and y dimensions of 88 and z dimension of 312, which yielded a reconstructed FOV of 4.4×4.4×15.6 cm. CT data were acquired using an x-ray voltage biased to 80 kVp with a 500-μA anode current, and the data were binned by a factor of 4 resulting in a projection size of 512×768. A 225 ms exposure was used and 360, 1°projections were collected. The data were reconstructed using an implementation of the Feldkamp-filtered back-projection algorithm [16] onto a 512×512×1,296 matrix with isotropic 0.11-mm voxels. 
Biodistribution and Autoradiography
Two groups of three 8-week-old H2-Ld-huIL-6 Tg Balb/c (C) female mice, 6 weeks post-AEF injection, were injected i.v. with 3.7 MBq of 125 I-SAP or 125 I-p5 peptide. The mice were sacrificed at 24 and 2 h post-SAP and p5 injection, respectively, as described above and organs harvested for micro-autoradiographic comparison as described below.
Samples of 12 tissues were harvested post-mortem from the three mice [17] . Each tissue was placed into a tarred, plastic vial and weighed. The radioactivity in the 125 I and 99m Tc energy windows was measured using an automated Wizard 3 gamma counter (1480 Wallac Gamma Counter, PerkinElmer) Tc-p5 peptide in mice with AA amyloidosis. Significantly more 125 I-SAP (blue) was retained by amyloid in the spleen as compared to 99m Tc-p5 (red); whereas more 99m Tc-p5 was observed in the pancreas, small intestines, and heart. *pG0.05, **pG0.01. using a crossover from high-to low-energy channel of 4.6% that was determined empirically using a pure sample of 99m Tc counted using the dual-energy windows. The calculated percent injected dose values were decay corrected to the time of injection by counting samples of the original injected material. Additional samples of tissue were fixed in 10% buffered formalin for 24 h and embedded in paraffin, and 6-μm-thick sections were cut onto Plus™ microscope slides (Fisher Scientific), dipped in NTB-2 emulsion (Eastman Kodak), stored in the dark, and developed after a 96-h exposure. Each section was counterstained with hematoxylin. The presence of amyloid deposits was microscopically confirmed in consecutive tissue sections viewed under cross-polarized illumination after staining with alkaline Congo red. All tissues were examined using a Leica DM500 light microscope fitted with cross-polarizing filters. Digital microscopic images were acquired using a cooled CCD camera (SPOT, Diagnostic Instruments, Sterling Heights, MI).
Specific Binding Studies
Cohorts of three 8-week-old H2-Ld-huIL-6 Tg Balb/c (C) transgenic mice at 6 weeks post-AEF injection received either 2 μg (∼100 μCi) of 125 I-p5 peptide alone or mixed with 500 μg of unlabeled peptide. At 2 h post-injection, the mice were euthanized by isoflurane inhalation and the organs harvested, and biodistribution of the radiotracer was determined as described above.
Results
SAP was radioiodinated with a radiochemical yield of ∼50% and purified to a radiochemical purity of 995%. Peptide p5 was coupled with 99m Tc with a radiochemical yield (decay corrected) of ∼75% and purified to a radiochemical purity of 990% (data not shown). Previous imaging experiments with 125 I-SAP and 125 I-p5 peptide had demonstrated that both agents imaged amyloid deposits, but there were differences in the relative uptake of each tracer, possibly resulting from differences in tracer affinity or possibly due to different amyloid burdens of the mice used. For a direct comparison of amyloid-binding efficacy, 125 
I-SAP and 99m
Tc-p5 peptide were both injected into three mice with AA amyloidosis. Conditions for imaging AA amyloid in this mouse model using 125 I-SAP have been established and were adapted from previous studies in humans where images were acquired at 24 h p.i. [12, 13, 18] . The optimal time for imaging 125 I-p5 was previously established [6] . We have demonstrated with dual-energy biodistribution experiments that 99m Tc-and 125 I-p5 peptide bind comparably (G30% difference) in the liver, spleen, and pancreas of mice with AA amyloidosis (data not shown). The distribution of radioactivity at 24 h p.i. of SAP and 2 h p.i. of peptide p5 was quantified by dual-energy gamma counting of tissue samples harvested at necropsy. Both radiotracers were readily detected in the liver, spleen, pancreas, and intestines, which are the major sites of amyloid deposition in these mice ( Table 2 , Fig. 1 ). In the liver, the radioactivity associated with SAP and p5 was equivalent (∼11%injected dose (ID)/g). In the spleen, however, Tc-p5 peptide (p=0.006), likely due to variable concentrations of SAP and p5 binding sites, or steric inhibition of the p5-amyloid interaction due to the extensive amyloid fibril deposits. In contrast, there was significantly more 99m Tc-p5 relative to SAP in the pancreas (p=0.006), small intestine (p=0.002), and heart (p=0.015). Although there was also greater than threefold more 99m Tc-p5 in the large intestine and cecum, the difference was not statistically significant (p= 0.075, for both tissues). Specific inhibition of 125 I-p5 binding to the liver, pancreas, and upper intestines was achieved with coinjection of 500 μg of unlabeled peptide, which resulted in a greater than twofold decrease in each tissue (p values of 0.04, 0.06, and 0.01, respectively).
The quantitative biodistribution data were confirmed in the dual-energy SPECT/CT images of each of the mice (Figs. 2  and 3) . The i.p. injection of CT contrast agent facilitated visualization of the organ and tissue boundaries. In mouse 1, retention of 99m Tc-p5 peptide was observed in the liver, spleen, intestines, and pancreas (Figs. 2a, c, and e) . No activity was observed in the stomach or thyroid-sites of 99m Tc and radioiodide accumulation in mammals [19] . In contrast, free (Figs. 2b, d , and f). This pattern of reactivity was similarly observed in the fused dual-energy SPECT images of each of the three mice studied (Fig. 3) .
By virtue of the i.p. contrast CT injection, the pancreas was identified in all three mice in the CT images, and when co-registered with the 99m Tc-p5 data, the amyloid-bound peptide was evidenced in this organ (Figs. 4a-c) . This was not observed in the 125 I-SAP SPECT/CT images. The significant increase in peptide p5 accumulation in the pancreas relative to SAP and the specific binding of both tracers to the amyloid deposits was confirmed by microautoradiography ( Fig. 4d and e) . For these experiments, it was necessary to use 125 I-labeled probes in separate mice with similar (4+) amyloid burden as evidenced by comparing Congo red-stained adjacent tissue sections since it was not possible to obtain high-resolution micro-autoradiographs with 99m Tc-p5. These results verified the organ amyloid distribution determined by dual-energy imaging.
Discussion
Visceral amyloidosis is an orphan condition with an incidence of ∼5,000 new cases per year in the USA. The clinical standard for the non-invasive, whole body detection of visceral amyloid is planar gamma scintigraphy using 123 I-SAP, which is available only in Europe [20] . The importance of this technique is supported by the fact that over ∼1,500 scans are performed annually in the UK alone, with numerous patients traveling from other countries to England to access this procedure. The image data are used not only to supplement laboratory diagnostic tests performed on tissue biopsies, but also to provide a picture of the whole body amyloid burden, which may influence treatment options and prognosis. The ability to non-invasively and repeatedly image a patient's amyloid load can be used to document response to therapy or relapse-a procedure that would be of benefit not only in routine clinical management but also during clinical trial evaluation of novel anti-amyloid therapeutics.
As an alternative to this technique, we have developed a radiolabeled heparin-binding peptide, designated p5, and evaluated it in mice with systemic AA amyloidosis. The peptide was shown by SPECT imaging, biodistribution, and micro-autoradiography to accumulate rapidly within amyloid-laden, but not healthy, organs and tissues [6] . To eliminate the effect of variation in amyloid deposition within individual mice, we used dual-isotope SPECT imaging to compare the efficacy of SAP and peptide p5 in individual animals. Dual-isotope SPECT imaging and tissue analysis afford a direct quantitative evaluation of the comparative efficacy of radiotracers in vivo and limit the confounding effects of heterogeneity in pathology and physiology in animal models of disease.
SPECT images were consistent with previous findings using radioiodinated SAP and p5 separately in different mice [6, 7, 12, 13] . The dual-energy approach demonstrated directly that peptide p5 imaged amyloid in organs not visualized by SAP in the same mouse, notably the pancreas and intestines. This may have resulted from the enhanced detection of highenergy 99m Tc photons due to the decreased scatter and attenuation relative to the 125 I-SAP-derived photons [21] ; however, biodistribution and autoradiography of excised, isolated, small tissue samples confirmed that peptide p5 was sequestered preferentially in the pancreas and intestines relative to SAP. This advantage may be due to the fact that the peptide is much smaller than SAP, facilitating trans-vascular wall migration and thus enhanced access to extravascular amyloid deposits. One apparent limitation evident from this study is the inability to specifically image renal amyloid using 99m Tc-p5 because it is cleared through the kidneys. To circumvent this, we anticipate using radioiodinated ( 124 I) p5 peptide for clinical imaging by using PET/CT. We have demonstrated that the p5 peptide not bound to amyloid deposits is dehalogenated rapidly within the kidneys during catabolism and that the free radioiodide is sequestered by the stomach and thyroid [6] . The amyloid-bound peptide is dehalogenated at a much slower rate (if at all). Thus, renal amyloid deposits may be visualized in patients by PET imaging using 124 I-p5 at time points that allow the clearance or dehalogenation of unbound peptide to occur.
Therefore, in addition to being chemically synthesized and rapidly cleared from the circulation, the increased tissue penetration and therefore enhanced amyloid labeling afford p5 certain advantages over SAP that may facilitate its translation to the clinic in the USA for imaging patients with visceral amyloidosis.
Conclusions
Radiolabeled p5 is capable of imaging amyloid deposits in liver and spleen of AA mice nearly as efficiently as SAP. In addition, images of p5 demonstrated amyloid in both pancreas and intestines providing a more complete picture of amyloid organ distribution in this animal model. Efforts are in progress to obtain FDA approval for clinical translation of p5 as a visceral amyloid-imaging agent in the USA.
